Bank of America
ARQT icon

Bank of America’s Arcutis Biotherapeutics ARQT Stock Holding History

Bank of America’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.3M Buy
2,221,289
+547,835
+33% +$14M ﹤0.01% 1569
2025
Q4 		$48.6M Buy
1,673,454
+784,169
+88% +$20.1M ﹤0.01% 1584
2025
Q3 		$16.8M Sell
889,285
-313,228
-26% -$4.94M ﹤0.01% 2782
2025
Q2 		$16.9M Buy
1,202,513
+687,562
+134% +$9.64M ﹤0.01% 2729
2025
Q1 		$8.05M Sell
514,951
-21,507
-4% -$303K ﹤0.01% 3358
2024
Q4 		$7.47M Sell
536,458
-639,447
-54% -$7.01M ﹤0.01% 3213
2024
Q3 		$10.9M Buy
1,175,905
+608,782
+107% +$6.01M ﹤0.01% 2982
2024
Q2 		$5.27M Sell
567,123
-283,406
-33% -$2.56M ﹤0.01% 3572
2024
Q1 		$8.43M Buy
850,529
+759,511
+834% +$5.67M ﹤0.01% 3144
2023
Q4 		$294K Sell
91,018
-259,945
-74% -$707K ﹤0.01% 5846
2023
Q3 		$1.86M Sell
350,963
-55,592
-14% -$473K ﹤0.01% 4316
2023
Q2 		$3.87M Sell
406,555
-1,215,219
-75% -$13.5M ﹤0.01% 3638
2023
Q1 		$17.8M Buy
1,621,774
+1,382,736
+578% +$20M ﹤0.01% 2233
2022
Q4 		$3.54M Buy
239,038
+87,781
+58% +$1.53M ﹤0.01% 3732
2022
Q3 		$2.89M Buy
151,257
+112,962
+295% +$2.56M ﹤0.01% 3937
2022
Q2 		$816K Buy
38,295
+28,295
+283% +$580K ﹤0.01% 5077
2022
Q1 		$193K Sell
10,000
-2,110
-17% -$35.7K ﹤0.01% 6488
2021
Q4 		$251K Buy
12,110
+5,600
+86% +$111K ﹤0.01% 6358
2021
Q3 		$156K Sell
6,510
-23
-0.4% -$525 ﹤0.01% 6460
2021
Q2 		$178K Sell
6,533
-23,828
-78% -$671K ﹤0.01% 6166
2021
Q1 		$878K Buy
30,361
+25,356
+507% +$792K ﹤0.01% 4944
2020
Q4 		$141K Buy
5,005
+486
+11% +$11.9K ﹤0.01% 5814
2020
Q3 		$132K Buy
4,519
+743
+20% +$19.9K ﹤0.01% 5528
2020
Q2 		$114K Sell
3,776
-896
-19% -$25.9K ﹤0.01% 5607
2020
Q1 		$139K Buy
+4,672
New +$126K ﹤0.01% 5321

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America's ARQT Position: Q1 2026 in Review

Bank of America increased its Arcutis Biotherapeutics (ARQT) stake by 33% in Q1 2026, buying an estimated $14M and bringing the position to 2,221,289 shares worth $52.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1569.

Bank of America first reported a position in ARQT in Q1 2020 and has held it in 25 quarters since. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Bank of America held 2,221,289 shares of Arcutis Biotherapeutics worth $52.3M as of Q1 2026.
  • Bank of America bought 547,835 Arcutis Biotherapeutics shares in Q1 2026, an estimated $14M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1569 holding.
  • Bank of America first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 25 quarters since.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.